Abstract 16697: Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From the American Heart Association’s Get With the Guidelines-Heart Failure Registry

BackgroundThe U.S. Food and Drug Administration (FDA) approved the angiotensin-receptor/neprilysin inhibitor (ARNI) sacubitril/valsartan for patients with heart failure with reduced ejection fraction (HFrEF) in July 2015. There is interest in characterizing early patterns of use of this novel therapy.ObjectiveUsing data from the AHA’s Get With The Guidelines-Heart Failure (GWTG-HF) Registry, we assessed the prevalence and variation in ARNI prescription among a real-world HF population.MethodsWe included patients discharged alive from hospitals in GWTG-HF between July 2015 and March 2016. We compared patient and hospital characteristics among HFrEF (EF≤40%) patients with and without ARNI prescription at discharge, excluding those missing information on whether ARNI was prescribed. To evaluate hospital variation, we assessed hospitals with at least 10 patients discharged during the study period.ResultsOf 13,831 HFrEF hospitalizations without documented contraindications, 221 (1.6%) were prescribed ARNI. Patients with HFrEF prescribed ARNI were younger (median age 63 vs. 70 years, P